期刊
JACC-HEART FAILURE
卷 3, 期 9, 页码 661-669出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jchf.2015.04.011
关键词
cardiac MRI; heart failure; myocardial recovery; myocardium
资金
- American Heart Association [13 POST 16820054]
- Heart Failure Society of America
- National Heart, Lung, and Blood Institute
- Agency for Healthcare Research and Quality
- Cubist Pharmaceuticals
- GLG (Gerson Lehman Group)
- National Institutes of Health
- European Union
- Health Resources Service Administration
- CardioCell
- Bayer
- Siemens
Myocardial recovery in heart failure (HF) is possible, but its determinants are not fully defined. At least partial functional improvement is possible with current evidence-based therapies. However, once significant HF symptoms develop, patients have varied trajectories, including: 1) structural and functional recovery; 2) stabilization (remission); and 3) acceleration to end-stage HF/death. All 3 trajectories may be interrupted by sudden death. These trajectories may represent the interplay of heterogeneous causality, genetic predeterminants, and disease phenotypes. Enhanced phenotypic description with cardiac magnetic resonance imaging, molecular imaging, or circulating biomarkers of the heterogeneous HF population may provide insights regarding specific biological targets amenable to existing and novel therapeutic strategies. The identification of patients in remission, before progression to the end stage of predominantly nonviable tissue (e.g., fibrosis), has implications for clinical practice and future trials because such patients may be more likely to experience myocardial recovery (cardiac reserve). The identification of dysfunctional but viable myocardium and its diverse pathophysiological causes may provide opportunities to investigate existing and novel therapeutics aimed at enhancing myocardial recovery. (C) 2015 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据